據(jù)9月4日的《科學(xué)》雜志報(bào)道說(shuō),，在大約20年的時(shí)間中，人們第一次發(fā)現(xiàn)了新的可中和HIV的廣譜性抗體,；這一發(fā)現(xiàn)產(chǎn)生了某些令人興奮的研發(fā)疫苗的新標(biāo)靶,。 Laura Walker及其同僚應(yīng)用高通量培養(yǎng)系統(tǒng)在一個(gè)HIV感染的非洲捐贈(zèng)者體內(nèi)辨識(shí)出了2種過(guò)去未被認(rèn)識(shí)的抗體。 這些抗體看來(lái)具有非常強(qiáng)效的中和病毒的作用,，它們還比其它已知的廣譜中和抗體能夠中和范圍更廣的來(lái)自許多不同分化枝（或群體）的病毒,。
研究人員說(shuō)，這些新發(fā)現(xiàn)的廣譜中和抗體的作用就像是一個(gè)能打開(kāi)某一隱藏的病毒之鎖的鑰匙,，它們能夠識(shí)別一個(gè)保守的HIV蛋白上的一個(gè)蛋白質(zhì)基序,，而這種基序是研究人員過(guò)去所沒(méi)有描述過(guò)的。 他們說(shuō),，這些抗體和新的蛋白基序的發(fā)現(xiàn)可能會(huì)為人們打開(kāi)令人深感興趣的未來(lái)HIV疫苗研發(fā)的新標(biāo)靶之門(mén),。（生物谷Bioon.com）
生物谷推薦原始出處：
Science DOI: 10.1126/science.1178746 September 3, 2009
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Laura M. Walker 1, Sanjay K. Phogat 2*, Po-Ying Chan-Hui 3, Denise Wagner 2, Pham Phung 4, Julie L. Goss 4, Terri Wrin 4, Melissa D. Simek 5, Steven Fling 1, Jennifer L. Mitcham 3, Jennifer K. Lehrman 5, Frances H. Priddy 5, Ole A. Olsen 3, Steven M. Frey 3, Phillip W. Hammond 3, Protocol G Principal Investigators , Stephen Kaminsky 2, Timothy Zamb 2, Matthew Moyle 3, Wayne C. Koff 5, Pascal Poignard 1, Dennis R. Burton 6*
1 Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.
2 Design Lab, International AIDS Vaccine Initiative, New York, NY 11226, USA.
3 Theraclone Sciences, Seattle, WA 98104, USA.
4 Monogram Biosciences, Inc., South San Francisco, CA 94080, USA.
5 International AIDS Vaccine Initiative, New York, NY 10038, USA.
6 Department of Immunology and Microbial Science, and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Techonology, and Harvard, Boston, MA 02114, USA.
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1–infected individuals, define critical epitopes for HIV vaccine design. Using a systematic approach, we have examined neutralization breadth in the sera of about 1800 HIV-1–infected individuals, primarily infected with non–clade B viruses, and have selected donors for monoclonal antibody (mAb) generation. We then used a high-throughput neutralization screen of antibody-containing culture supernatants from approximately 30,000 activated memory B cells from a clade A–infected African donor to isolate two potent mAbs that target a broadly neutralizing epitope. This epitope is preferentially expressed on trimeric Envelope protein and spans conserved regions of variable loops of the gp120 subunit. The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses.
